On February 28, 2001, the U.S. Food and Drug Administration (FDA) approved Reminyl® (galantamine hydrobromide) for the treatment of mild to moderate Alzheimer's disease. Data from placebo-controlled, double-blind clinical trials involving more than 2,650 patients show that Reminyl can have a beneficial effect on patients' daily function and ability to think. Developed by the Janssen Research Foundation, a wholly owned subsidary of Johnson & Johnson, and under a codevelopment and licensing agreement with the UK-based Shire Pharmaceuticals Group plc., Reminyl has been approved in 21 other countries to date. The drug will be available by prescription in the U.S. in May in 4 mg, 8 mg, or 12 mg tablets. Common side effects of the drug are gastrointestinal in nature, with a small percentage of patients experiencing nausea, vomiting, anorexia, diarrhea and weight loss.—Hakon Heimer


No Available Comments

Make a Comment

To make a comment you must login or register.


No Available References

Further Reading

No Available Further Reading